Ariceum Therapeutics Revenue
Biotechnology Research • 
Berlin, Berlin, Germany • 21-50 Employees
Ariceum Therapeutics revenue & valuation
| Annual revenue | $1,000,000 |
| Revenue per employee | $29,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,200,000 |
| Total funding | $25,000,000 |
Key Contacts at Ariceum Therapeutics
Jessica Klaver Preston
Global Director-Clinical Operations/Site Engagement
Pierre Jordaan
Director Pharmacovigilance
Manuel Sturzbecher-Hoehne
Chief Technology Officer, Cto
Aaron Block
Senior Director Business Development
Charles Oleforo
Associate Director Quality Assurance
Anika Jakel
Senior Director
Company overview
| Headquarters | Robert-Rössle-Straße. 10, Building 79, Berlin, 13125, DE |
| Phone number | +493094893360 |
| Website | |
| NAICS | 541714 |
| Founded | 2021 |
| Employees | 21-50 |
| Socials |
Ariceum Therapeutics Email Formats
Ariceum Therapeutics uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@ariceum-therapeutics.com), used 65.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@ariceum-therapeutics.com | 69.5% |
{first initial}.{last name} | j.doe@ariceum-therapeutics.com | 30.4% |
About Ariceum Therapeutics
Ariceum Therapeutics is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical candidate, SSO110 (“satoreotide”) labelled with Lutetium-177 (177Lu) and Actinium-255 (255Ac) is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in aggressive neuroendocrine tumours (NETs) such as small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC), all of which have limited treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic pair’ for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023. Ariceum Therapeutics, launched in 2021, acquired all rights to satoreotide from Ipsen, which has remained a shareholder of the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, the United Kingdom, and the United States. Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Ariceum Therapeutics has 13 employees across 7 departments.
Departments
Number of employees
Ariceum Therapeutics Tech Stack
Discover the technologies and tools that power Ariceum Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Maps
JavaScript libraries
Font scripts
JavaScript libraries
Webmail
Programming languages
Blogs
Analytics
Tag managers
Reverse proxies
JavaScript libraries
United Kingdom
Switzerland
Spain
Frequently asked questions
4.8
40,000 users
